指南与共识心血管US

超声心动图与接受多巴胺激动剂治疗的高催乳素血症患者的监测:英国超声心动图学会、英国心脏瓣膜学会和内分泌学会的联合立场声明

Echocardiography and monitoring patients receiving dopamine agonist therapy for hyperprolactinaemia: a joint position statement of the British Society of Echocardiography, the British Heart Valve Society and the Society for Endocrinology.
指南 / 共识 · Echo Res Pract · 2019-01-01

该联合立场声明指出,多巴胺激动剂治疗高催乳素血症导致异常瓣膜形态和功能的证据极为有限,除个案报告外无临床显著瓣膜病变证据。不应将瓣膜反流程度变化归因于多巴胺激动剂,除非伴有瓣叶增厚、受限或回缩等病理改变。建议治疗前行标准经胸超声心动图,并根据卡麦角林每周总剂量(≤2 mg 者 5 年复查,>2 mg 者每年复查)进行监测。

要点

  • 多巴胺激动剂治疗高催乳素血症导致临床显著瓣膜病变的证据缺失,仅有个案报告。
  • 无瓣叶增厚、受限或回缩时,不应将瓣膜反流程度变化归因于多巴胺激动剂。
  • 卡麦角林每周总剂量≤2 mg 者起始后 5 年复查,>2 mg 者每年复查超声心动图。

核心结论

  • 多巴胺激动剂治疗高催乳素血症引起异常瓣膜形态和功能的证据极为有限,除个案报告外无临床显著瓣膜病理证据。
  • 无瓣叶厚度、受限或回缩相关病理改变时,应避免将瓣膜反流程度变化归因于多巴胺激动剂的不良反应。

研究设计与样本

  • 英国超声心动图学会、英国心脏瓣膜学会和内分泌学会的联合立场声明,制定方法与证据分级原文未报告。

关键影像表现/征象

  • 瓣膜反流程度变化需结合瓣叶厚度、受限或回缩等形态学改变评估,无相关病理改变时不应归因于多巴胺激动剂。
  • 即使怀疑瓣叶结构和功能形态改变,超声心动图分级为半定量,可能因不同机器、超声设置和操作者而异。

诊断标准与关键数值

  • 推荐在开始多巴胺激动剂治疗高催乳素血症前进行标准经胸超声心动图。
  • 服用卡麦角林每周总剂量小于或等于 2 mg 的患者,起始后 5 年复查经胸超声心动图;若 5 年扫描无变化,可继续每 5 年复查。
  • 服用卡麦角林每周总剂量超过 2 mg 的患者,推荐每年进行超声心动图检查。
  • 停药决定应仅在经验丰富的超声心动图医师审阅系列影像后做出,该医师需擅长分析药物性瓣膜病或类癌心脏病。

临床应用与阅片要点

  • 开始多巴胺激动剂治疗高催乳素血症前应行标准经胸超声心动图作为基线。
  • 报告瓣膜反流程度变化时,需同时描述瓣叶厚度、受限或回缩等形态学改变,避免孤立归因于药物。
  • 注意超声心动图分级为半定量,不同机器、设置和操作者间可能存在差异。

局限性

  • 多巴胺激动剂导致异常瓣膜形态和功能的证据极为有限。
  • 临床显著瓣膜病理证据缺失,仅有个案报告且围绕其仍存疑问。
  • 超声心动图对瓣膜形态和功能的分级为半定量,可能因不同机器、超声设置和操作者而异。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

This is a joint position statement of the British Society of Echocardiography, the British Heart Valve Society and the Society for Endocrinology on the role of echocardiography in monitoring patients receiving dopamine agonist (DA) therapy for hyperprolactinaemia. (1) Evidence that DA pharmacotherapy causes abnormal valve morphology and dysfunction at doses used in the management of hyperprolactinaemia is extremely limited. Evidence of clinically significant valve pathology is absent, except for isolated case reports around which questions remain. (2) Attributing change in degree of valvular regurgitation, especially in mild and moderate tricuspid regurgitation, to adverse effects of DA in hyperprolactinaemia should be avoided if there are no associated pathological changes in leaflet thickness, restriction or retraction. It must be noted that even where morphological change in leaflet structure and function may be suspected, grading is semi-quantitative on echocardiography and may vary between different machines, ultrasound settings and operators. (3) Decisions regarding discontinuation of medication should only be made after review of serial imaging by an echocardiographer experienced in analysing drug-induced valvulopathy or carcinoid heart disease. (4) A standard transthoracic echocardiogram should be performed before a patient starts DA therapy for hyperprolactinaemia. Repeat transthoracic echocardiography should then be performed at 5 years after starting cabergoline in patients taking a total weekly dose less than or equal to 2 mg. If there has been no change on the 5-year scan, repeat echocardiography could continue at 5-yearly intervals. If a patient is taking more than a total weekly dose of 2 mg, then annual echocardiography is recommended.

来源:Echo Res Pract,查看原文。版权归原作者所有。

引用

  1. Steeds RP, Stiles CE, Sharma V, et al. Echocardiography and monitoring patients receiving dopamine agonist therapy for hyperprolactinaemia: a joint position statement of the British Society of Echocardiography, the British Heart Valve Society and the Society for Endocrinology. Echo Res Pract. 2019. PMID: 30825409. doi:10.1530/ERP-18-0069

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。